ESTRO 2022 - Abstract Book

S1143

Abstract book

ESTRO 2022

Conclusion Our data suggests that the optimal timepoint for assessment of complete clinical response after chemoradiation for LACC patients could be 6 months after exclusive treatment completion. This longer timeline could include patients not yet responders after 3 months, avoiding too early rescue therapies. Further and larger studies are needed to confirm this finding.

PO-1348 Prognostic factors in patients receiving palliative radiotherapy for female genital tract cancer

S.H. Kombathula 1 , A. Cree 1,2 , P.V. Joshi 3 , N. Akturk 1 , L.H. Barraclough 1 , K. Haslett 1 , A. Choudhury 1 , P. Hoskin 1,3

1 The Christie NHS Foundation Trust, Clinical Oncology, Manchester, United Kingdom; 2 The Clatterbridge Cancer Centre, Clinical Oncology, Liverpool, United Kingdom; 3 Mount Vernon Cancer Centre, Clinical Oncology, Northwood, United Kingdom Purpose or Objective The 5 year survival of female genital tract cancer (FGTC) is approximately 15%. In the management of advanced female genital tract cancer (FGTC), palliative radiotherapy plays an important role. There is little data reporting the outcome of palliative radiotherapy in this setting and the quality of evidence available for prognostic indicators to inform patient selection is suboptimal. Materials and Methods Data of patients receiving palliative radiotherapy for FGTC was collected retrospectively including patient demographics, disease and treatment characteristics from two UK cancer centres. Overall survival was calculated from the date of completion of radiotherapy using the Kaplan Meier method. Descriptive statistics were used for quantitative variables. The association between the patient, disease and, treatment factors and the survival after completion of radiotherapy was analysed using ANOVA with a significance threshold of p=0.05. Results A total of 184 patients were included in the study. Table-1 shows baseline patient demographics. Of all patients, 35.3% received prior radical treatment for FGTC and then subsequently relapsed. The radiotherapy schedules used varied significantly and ranged from 10Gy/1# to more protracted regimens like 50Gy/20# but the most commonly used regimen was 35Gy/15#(33.6%). The prescribed regimens were well tolerated with only 1.7% unable to complete the planned course of palliative radiotherapy. Most patients (40.7%) did not experience acute toxicity related to palliative radiotherapy,